Mechanisms of STAT3 activation in the liver of FXR knockout mice.

Farnesoid X receptor (FXR, Nr1h4) is a ligand-activated transcription factor belonging to the nuclear receptor superfamily. FXR is essential in maintaining bile acid (BA) homeostasis, and FXR(-/-) mice develop cholestasis, inflammation, and spontaneous liver tumors. The signal transducer and activator of transcription 3 (STAT3) is well known to regulate liver growth, and STAT3 is feedback inhibited by its target gene, the suppressor of cytokine signaling 3 (SOCS3). Strong activation of STAT3 was detected in FXR(-/-) mouse livers. However, the mechanism of STAT3 activation with FXR deficiency remains elusive. Wild-type (WT) and FXR(-/-) mice were used to detect STAT3 pathway activation in the liver. In vivo BA feeding or deprivation was used to determine the role of BAs in STAT3 activation, and in vitro molecular approaches were used to determine the direct transcriptional regulation of SOCS3 by FXR. STAT3 was activated in FXR(-/-) but not WT mice. BA feeding increased, but deprivation by cholestyramine reduced, serum inflammatory markers and STAT3 activation. Furthermore, the Socs3 gene was determined as a direct FXR target gene. The elevated BAs and inflammation, along with reduced SOCS3, collectively contribute to the activation of the STAT3 signaling pathway in the liver of FXR(-/-) mice. This study suggests that the constitutive activation of STAT3 may be a mechanism of liver carcinogenesis in FXR(-/-) mice.

[1]  Hua Yu,et al.  Deletion of IFNγ enhances hepatocarcinogenesis in FXR knockout mice. , 2012, Journal of hepatology.

[2]  Rajagopal N. Aravalli,et al.  Cellular and molecular mechanisms of hepatocellular carcinoma: an update , 2012, Archives of Toxicology.

[3]  Young Woo Kim,et al.  Farnesoid X receptor protects hepatocytes from injury by repressing miR-199a-3p, which increases levels of LKB1. , 2012, Gastroenterology.

[4]  Ann M. Thomas,et al.  Farnesoid X Receptor Induces Murine Scavenger Receptor Class B Type I via Intron Binding , 2012, PloS one.

[5]  Taosheng Chen,et al.  A tea catechin, epigallocatechin-3-gallate, is a unique modulator of the farnesoid X receptor. , 2012, Toxicology and applied pharmacology.

[6]  Kuen-Feng Chen,et al.  Dovitinib Induces Apoptosis and Overcomes Sorafenib Resistance in Hepatocellular Carcinoma through SHP-1–Mediated Inhibition of STAT3 , 2011, Molecular Cancer Therapeutics.

[7]  Andy Wolfe,et al.  Increased Activation of the Wnt/β-Catenin Pathway in Spontaneous Hepatocellular Carcinoma Observed in Farnesoid X Receptor Knockout Mice , 2011, Journal of Pharmacology and Experimental Therapeutics.

[8]  B. Gao,et al.  Signal Transducer and Activator of Transcription 3 in Liver Diseases: A Novel Therapeutic Target , 2011, International journal of biological sciences.

[9]  G. Guo,et al.  Tissue-specific function of farnesoid X receptor in liver and intestine. , 2011, Pharmacological research.

[10]  Ann M. Thomas,et al.  Farnesoid X receptor activation mediates head-to-tail chromatin looping in the Nr0b2 gene encoding small heterodimer partner. , 2010, Molecular endocrinology.

[11]  Xiaohui Xie,et al.  Genome-wide interrogation of hepatic FXR reveals an asymmetric IR-1 motif and synergy with LRH-1 , 2010, Nucleic acids research.

[12]  Ann M. Thomas,et al.  Genome‐wide tissue‐specific farnesoid X receptor binding in mouse liver and intestine , 2010, Hepatology.

[13]  M. Karin,et al.  Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. , 2010, Cancer cell.

[14]  B. Copple,et al.  Upregulation of early growth response factor-1 by bile acids requires mitogen-activated protein kinase signaling. , 2010, Toxicology and applied pharmacology.

[15]  Hua Yu,et al.  STATs in cancer inflammation and immunity: a leading role for STAT3 , 2009, Nature Reviews Cancer.

[16]  B. Aggarwal,et al.  Signal Transducer and Activator of Transcription‐3, Inflammation, and Cancer , 2009, Annals of the New York Academy of Sciences.

[17]  Songwen Zhang,et al.  Suppression of interleukin-6-induced C-reactive protein expression by FXR agonists. , 2009, Biochemical and biophysical research communications.

[18]  Ann M. Thomas,et al.  Farnesoid X Receptor Deficiency in Mice Leads to Increased Intestinal Epithelial Cell Proliferation and Tumor Development , 2009, Journal of Pharmacology and Experimental Therapeutics.

[19]  B. M. Forman,et al.  Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response , 2008, Hepatology.

[20]  B. M. Forman,et al.  Farnesoid X receptor protects liver cells from apoptosis induced by serum deprivation in vitro and fasting in vivo. , 2008, Molecular endocrinology.

[21]  M. Karin,et al.  The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. , 2008, Trends in molecular medicine.

[22]  C. Porta,et al.  Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  Hui-yu Liu,et al.  Regulation of Interleukin-6-induced Hepatic Insulin Resistance by Mammalian Target of Rapamycin through the STAT3-SOCS3 Pathway* , 2008, Journal of Biological Chemistry.

[24]  Wei Zhang,et al.  Transfer of suppressor of cytokine signaling 3 by an oncolytic adenovirus induces potential antitumor activities in hepatocellular carcinoma , 2007, Hepatology.

[25]  J. Ward,et al.  Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. , 2007, Carcinogenesis.

[26]  Yun Yen,et al.  Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. , 2007, Cancer research.

[27]  Y. Maehara,et al.  Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. , 2006, Gastroenterology.

[28]  Kenichi Matsubara,et al.  Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma , 2005, Oncogene.

[29]  S. Kliewer,et al.  Complementary Roles of Farnesoid X Receptor, Pregnane X Receptor, and Constitutive Androstane Receptor in Protection against Bile Acid Toxicity* , 2003, Journal of Biological Chemistry.

[30]  Donald Metcalf,et al.  SOCS3 negatively regulates IL-6 signaling in vivo , 2003, Nature Immunology.

[31]  D. Moore,et al.  Bile acids regulate the ontogenic expression of ileal bile acid binding protein in the rat via the farnesoid X receptor. , 2002, Gastroenterology.

[32]  Masahiro Tohkin,et al.  Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis , 2000, Cell.

[33]  J. Lehmann,et al.  Bile acids: natural ligands for an orphan nuclear receptor. , 1999, Science.

[34]  M. Makishima,et al.  Identification of a nuclear receptor for bile acids. , 1999, Science.

[35]  Jasmine Chen,et al.  Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. , 1999, Molecular cell.

[36]  Warren S. Alexander,et al.  A family of cytokine-inducible inhibitors of signalling , 1997, Nature.

[37]  B. Kong,et al.  Mechanism of tissue‐specific farnesoid X receptor in suppressing the expression of genes in bile‐acid synthesis in mice , 2012, Hepatology.

[38]  D. Moore,et al.  Isolation of proteins that interact specifically with the retinoid X receptor: two novel orphan receptors. , 1995, Molecular endocrinology.